Skip to main content
Premium Trial:

Request an Annual Quote

Tecan and Dynal Biotech to Co-Develop Variety of Molecular Biology Applications

NEW YORK, Nov. 2 (GenomeWeb News) - Tecan and Dynal Biotech will co-develop and market optimized applications for separating, isolating, and manipulating biological material such as DNA, RNA, and proteins.


Under the terms of the non-exclusive agreement, which was originally announced on Oct. 15, the companies will develop applications using Dynal's Dynabeads magnetic bead kits and Tecan's Freedom EVO automated platform. Specific applications will include nucleic-acid extraction and preparation; PCR and sequencing clean-up procedures; and isolating recombinant proteins.


Financial details of the agreement were not disclosed.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.